Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Liabilities from Discontinued Operations (2023 - 2025)

Historic Liabilities from Discontinued Operations for Kyntra Bio (KYNB) over the last 3 years, with Q2 2025 value amounting to $8.5 million.

  • Kyntra Bio's Liabilities from Discontinued Operations changed N/A to $8.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $8.5 million, marking a year-over-year change of. This contributed to the annual value of $38.9 million for FY2024, which is 1056.85% down from last year.
  • As of Q2 2025, Kyntra Bio's Liabilities from Discontinued Operations stood at $8.5 million.
  • Over the past 5 years, Kyntra Bio's Liabilities from Discontinued Operations peaked at $43.5 million during Q4 2023, and registered a low of $8.3 million during Q1 2025.
  • In the last 3 years, Kyntra Bio's Liabilities from Discontinued Operations had a median value of $23.7 million in 2024 and averaged $24.8 million.
  • The largest annual percentage gain for Kyntra Bio's Liabilities from Discontinued Operations in the last 5 years was 1056.85% (2024), contrasted with its biggest fall of 1056.85% (2024).
  • Kyntra Bio's Liabilities from Discontinued Operations (Quarter) stood at $43.5 million in 2023, then decreased by 10.57% to $38.9 million in 2024, then plummeted by 78.27% to $8.5 million in 2025.
  • Its Liabilities from Discontinued Operations was $8.5 million in Q2 2025, compared to $8.3 million in Q1 2025 and $38.9 million in Q4 2024.